ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
3.240
-0.100 (-2.99%)
At close: Jun 11, 2025, 4:00 PM
3.250
+0.010 (0.31%)
Pre-market: Jun 12, 2025, 6:01 AM EDT
ImmunityBio Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for ImmunityBio stock ranges from a low of $5.00 to a high of $30. The average analyst price target of $11.4 forecasts a 251.85% increase in the stock price over the next year.
Price Target: $11.40 (+251.85%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +146.91% | Jun 4, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +825.93% | Jun 3, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +825.93% | May 28, 2025 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $4.25 → $5 | Hold → Buy | Upgrades | $4.25 → $5 | +54.32% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +146.91% | May 12, 2025 |
Financial Forecast
Revenue This Year
98.00M
from 14.75M
Increased by 564.61%
Revenue Next Year
256.63M
from 98.00M
Increased by 161.88%
EPS This Year
-0.50
from -0.62
EPS Next Year
-0.28
from -0.50
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 130.2M | 353.1M | 1.3B | ||
| Avg | 98.0M | 256.6M | 897.1M | ||
| Low | 81.9M | 174.1M | 549.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 783.0% | 260.3% | 390.6% | ||
| Avg | 564.6% | 161.9% | 249.5% | ||
| Low | 455.1% | 77.6% | 114.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.44 | -0.23 | 0.54 | ||
| Avg | -0.50 | -0.28 | 0.08 | ||
| Low | -0.57 | -0.33 | -0.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.